Sherry Washburn
Family · Grand Rapids, MINPI 1154671527
Payments from drug & device makers
Across 399 payments — averaging $15.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$946
- Supernus Pharmaceuticals, Inc.$705
- AstraZeneca$529
- Pfizer$479
- GSK$404
- Otsuka America Pharmaceutical, Inc.$391
- plus $3K from 32 others
What the payments were for
- Food & beverage$6,17699%
- Education$471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 68 | $946 |
| Supernus Pharmaceuticals, Inc. | 64 | $705 |
| AstraZeneca | 31 | $529 |
| Pfizer | 27 | $479 |
| GSK | 28 | $404 |
| Otsuka America Pharmaceutical, Inc. | 28 | $391 |
| Novo Nordisk | 25 | $376 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 18 | $328 |
| Orexo US, Inc. | 17 | $301 |
| Indivior Inc. | 15 | $258 |
| Lundbeck LLC | 8 | $196 |
| Lilly USA, LLC | 8 | $149 |
| Johnson & Johnson | 5 | $123 |
| Braeburn Inc. | 5 | $107 |
| Alkermes, Inc. | 5 | $102 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $96 |
| E.r. Squibb & Sons, L.L.C. | 5 | $95 |
| Exact Sciences | 5 | $78 |
| Boehringer Ingelheim | 4 | $62 |
| Astellas Pharma US Inc | 2 | $55 |
| Phathom Pharmaceuticals, Inc. | 3 | $52 |
| Paratek Pharmaceuticals, Inc. | 3 | $49 |
| Bayer | 2 | $42 |
| Axsome Therapeutics, Inc. | 2 | $38 |
| Tonix Medicines, Inc. | 1 | $27 |
| Amgen | 2 | $26 |
| Novartis | 1 | $24 |
| Teva Pharmaceuticals USA, Inc. | 1 | $23 |
| Biohaven Pharmaceuticals, Inc. | 1 | $20 |
| Antares Pharma, Inc. | 1 | $18 |
| Aimmune Therapeutics, Inc. | 1 | $18 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Ardelyx, Inc. | 1 | $16 |
| Pear Therapeutics (US), Inc. | 1 | $16 |
| Avanir Pharmaceuticals, Inc. | 1 | $16 |
| Electromed, Inc. | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Baxter Healthcare | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$243
How this compares
$6,223 in reported general payments places this provider in the 95th percentile of 3,657 family providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 323 | $43,795 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 58 | $36,853 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 67 | $31,614 |
| LinzessLinaclotide | 36 | $22,647 |
| FarxigaDapagliflozin Propanediol | 25 | $20,281 |
| WegovySemaglutide | 11 | $14,251 |
| MyrbetriqMirabegron | 16 | $9,217 |
| JardianceEmpagliflozin | 12 | $7,000 |
| TrintellixVortioxetine Hydrobromide | 12 | $5,200 |
| Atorvastatin Calcium | 152 | $2,331 |
| Lacosamide | 14 | $1,918 |
| Levothyroxine Sodium | 109 | $1,888 |
| Omeprazole | 138 | $1,872 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $1,845 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 49 | $1,506 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Orexo US, Inc.Zubsolv | $301 | $36,85358 claims |
| Indivior Inc.Suboxone | $258 | $31,61467 claims |
| AbbVieLinzess | $946 | $22,64736 claims |
| AstraZenecaFarxiga | $529 | $20,28125 claims |
| Novo NordiskWegovy | $376 | $14,25111 claims |
| Astellas Pharma US IncMyrbetriq | $55 | $9,21716 claims |
| Boehringer IngelheimJardiance | $62 | $7,00012 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $96 | $5,20012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,657 family providers in Michigan.
Other family in Grand Rapids
- Kelsey PrinceGrand Rapids$87K
- Marlee BogemaGrand Rapids$15K
- Jayme HeimGrandville$663K
- Susan WolgamottBloomfield Township$327K
- Elisheva EllenbergDetroit$150K
- Sarah JohnsonFarmington Hills$119K
- Daniela MaximTroy$112K
- Brent MillerFremont$66K
- Rachael CompeauFlint$62K
- David KocendaLapeer$49K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.